FACT CORP (FCTOA): CFO Jacqueline Mae Tucker Bought 200,000 Shares
CFO of (FCTOA) Jacqueline Mae Tucker bought 200,000 shares on 11/01/2010 at an average price of $0.25.
CFO Jacqueline Mae Tucker bought shares of FCTOA stock.
Generex Biotechnology Corp. (GNBT): COO, CFO& Treas. Rose C Perri Bought 54,000 Shares
COO, CFO& Treas. of Generex Biotechnology Corp. (GNBT) Rose C Perri bought 54,000 shares on 10/27/2010 at an average price of $0.35. Generex Biotechnology Corp. is engaged in the research and development of drug delivery technology primarily involving the administration of proprietary formulations of large molecule drugs to the oral cavityusing a hand-held aerosol applicator. Generex Biotechnology Corp. has a market cap of $104.05 million; its shares were traded at around $0.305 with and P/S ratio of 88.93.
GNBT is in the portfolios of Jim Simons of Renaissance Technologies LLC.
CEO & Pres. Anna E Gluskin and COO, CFO& Treas. Rose C Perri bought shares of GNBT stock.
Competitive Technologies, Inc (CTTC): CEO, CFO Johnnie D Johnson Bought 29,528 Shares
Competitive Technologies, Inc (CTTC) Johnnie D Johnson bought 29,528 shares on 10/28/2010 at an average price of $1.25. COMPETITIVE TECHNOLOGIES, INC is engaged primarily in providing technology management services to universities, to federal agencies and laboratories, and to corporations with the goal of maximizing returns on clients' investments in technology.
Competitive Technologies, Inc. announced its financial results for the fiscal fourth quarter and full year ended July 31, 2010. Operating expenses increased to $4.2 million for fiscal 2010, up from $3.8 million in fiscal 2009, with most of the increase due to Calmare medical device rollout expenses, including the Company's appearance at medical conferences in Boston and Chicago and other similar expenses. Operating expenses in the fourth quarter of fiscal 2010 were $1.1 million. The company have increased our revenue for fiscal 2010 to $2.0 million from $0.3 million for the prior fiscal year. Our revenue has doubled each successive fiscal 2010 quarter, based on the first quarter of fiscal 2010. The revenue for the fourth quarter of fiscal 2010 was $1.1 million.
CEO, CFO Johnnie D Johnson bought shares of CTTC stock.
Endologix Inc (ELGX): CFO Robert John Krist Bought 5,000 Shares
CFO of Endologix Inc (ELGX) Robert John Krist bought 5,000 shares on 11/03/2010 at an average price of $5.6. Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. Endologix Inc has a market cap of $288.9 million; its shares were traded at around $6.02 with and P/S ratio of 5.5.
Endologix, Inc. developer of minimally invasive treatments for aortic disorders, today announced financial results for the three and nine months ended September 30, 2010. Total revenue in the third quarter of 2010 was $17.9 million, a 30% increase from $13.8 million in the third quarter of 2009. Endologix reported a net loss for the third quarter of 2010 of $466,000 or $(0.01) per share, compared with a net loss of $156,000 or $(0.00) per share, for the third quarter of 2009.
ELGX is in the portfolios of Pioneer Investments.
CEO John D Mcdermott sold shares of ELGX stock.
CFO Robert John Krist bought shares of ELGX stock.
ArthroCare Corp. (ARTC): Sr VP and CFO Todd Newton Bought 3,500 Shares
Sr VP and CFO of ArthroCare Corp. (ARTC) Todd Newton bought 3,500 shares on 11/04/2010 at an average price of $28.22. ArthroCare Corp. is a medical device company that develops, manufactures and markets products based on its patented Coblation technology. Arthrocare Corp. has a market cap of $773.4 million; its shares were traded at around $28.47 with and P/S ratio of 2.4.
ArthroCare Corp. announced its financial results for the third quarter ended September 30, 2010. Total revenue for the third quarter of 2010 was $87.9 million, compared to $79.5 million for the third quarter of 2009. Product sales increased in both the Company's core Sports Medicine and ENT businesses. Net income available to common stockholders was $8.4 million, or $0.25 per diluted share in the third quarter of 2010, compared to a net loss available to common stockholders of $31.7 million, or ($1.18) per share, in the third quarter of 2009.
ARTC is in the portfolios of Stanley Druckenmiller of Duquesne Capital Management, LLC, John Hussman of Hussman Economtrics Advisors, Inc., Steven Cohen of SAC Capital Advisors, Mario Gabelli of GAMCO Investors, Pioneer Investments, Chuck Royce of Royce& Associates, George Soros of Soros Fund Management LLC.
Sr VP and CFO Todd Newton and Board of Directors David Fitzgerald bought shares of ARTC stock.
Sr VP, Strategic Business Unit James L Pacek sold shares of ARTC stock.
For the complete list of stocks that bought by their CFOs, go to: Insider Buys.